Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Acute Leukemia of Ambiguous Lineage in Relapse”

51 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 51 results

Early research (Phase 1)Looking for participantsNCT06177067
What this trial is testing

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Who this might be right for
Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaAcute Leukemia of Ambiguous Lineage
St. Jude Children's Research Hospital 24
Early research (Phase 1)Ended earlyNCT00933985
What this trial is testing

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Who this might be right for
Acute Leukemias of Ambiguous LineageAcute Undifferentiated LeukemiaAngioimmunoblastic T-cell Lymphoma+26 more
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT04975919
What this trial is testing

Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Biphenotypic LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Biphenotypic Leukemia+1 more
M.D. Anderson Cancer Center 20
Early research (Phase 1)Active Not RecruitingNCT06325748
What this trial is testing

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Who this might be right for
AML/MDSCD33 Expressing Hematological MalignanciesFLT3 Expressing Hematological Malignancies
Senti Biosciences 21
Testing effectiveness (Phase 2)Looking for participantsNCT03683433
What this trial is testing

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Who this might be right for
Acute Bilineal LeukemiaAcute Biphenotypic LeukemiaChronic Myelomonocytic Leukemia+4 more
M.D. Anderson Cancer Center 50
Early research (Phase 1)WithdrawnNCT03807063
What this trial is testing

Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant

Who this might be right for
Acute Bilineal LeukemiaMyelodysplastic/Myeloproliferative NeoplasmMyelodysplastic/Myeloproliferative Neoplasm, Unclassifiable+9 more
Fred Hutchinson Cancer Center
Early research (Phase 1)Study completedNCT05326516
What this trial is testing

Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Who this might be right for
Relapsed/Refractory LeukemiasAcute Lymphoblastic LeukemiaAcute Lymphocytic Leukemia+3 more
Syndax Pharmaceuticals 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05761171
What this trial is testing

Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Who this might be right for
Recurrent Acute Leukemia of Ambiguous LineageRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage+9 more
Children's Oncology Group 78
Testing effectiveness (Phase 2)Looking for participantsNCT07256210
What this trial is testing

Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic T-cell LeukemiaMixed Phenotype Acute Leukemia
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 15
Early research (Phase 1)Study completedNCT01231919
What this trial is testing

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Leukemias of Ambiguous LineageAcute Myeloid Leukemia/Transient Myeloproliferative Disorder+48 more
National Cancer Institute (NCI) 45
Early research (Phase 1)Ended earlyNCT04526795
What this trial is testing

Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

Who this might be right for
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Lymphoblastic Leukemia+8 more
M.D. Anderson Cancer Center 19
Testing effectiveness (Phase 2)Study completedNCT02397720
What this trial is testing

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

Who this might be right for
Acute Bilineal LeukemiaAcute Biphenotypic LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome+6 more
M.D. Anderson Cancer Center 150
Not applicableLooking for participantsNCT05794880
What this trial is testing

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

Who this might be right for
LeukemiaAcute Myeloid Leukemia in RemissionMyelodysplasia+10 more
Medical College of Wisconsin 40
Testing effectiveness (Phase 2)Ended earlyNCT04501614
What this trial is testing

Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Who this might be right for
Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)Ph+ Mixed Phenotype Acute Leukemia (MPAL)Philadelphia Chromosome-Like ALL (Ph-like ALL)
Takeda 11
Testing effectiveness (Phase 2)Looking for participantsNCT03670966
What this trial is testing

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Who this might be right for
Acute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia in Remission+9 more
Fred Hutchinson Cancer Center 30
Early research (Phase 1)Study completedNCT01319864
What this trial is testing

POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients

Who this might be right for
Relapsed/Refractory AMLRelapsed/Refractory ALLSecondary AML/MDS+3 more
Seattle Children's Hospital 20
Early research (Phase 1)Ended earlyNCT01887587
What this trial is testing

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Who this might be right for
Relapsed or Refractory Acute Lymphoblastic LeukemiaRelapsed or Refractory Lymphoblastic LymphomaMixed Phenotype Acute Leukemia
Ehab L Atallah 5
Early research (Phase 1)Study completedNCT01431664
What this trial is testing

AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia

Who this might be right for
Leukemia
Cancer Research UK 7
Testing effectiveness (Phase 2)Looking for participantsNCT04047641
What this trial is testing

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaBlasts 20 Percent or More of Bone Marrow Nucleated CellsHigh Risk Myelodysplastic Syndrome+5 more
M.D. Anderson Cancer Center 80
Testing effectiveness (Phase 2)Looking for participantsNCT04726241
What this trial is testing

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic Therapy+5 more
PedAL BCU, LLC 960
Load More Results